Choline PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/MRI for follow-up of a patient with a clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for follow-up of a patient with a clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments. PET Using Other Agents: There are many additional prostate-specific tracers that are not FDA approved, including 11C-acetate [70,71], 18F-choline [72-74], Bombesin, 18F-fluorodihydrotestosterone [78] that are in various stages of investigation and have been reported to detect local and metastatic recurrent disease in patients with biochemical failure after local treatment. These agents remain investigational, but some have shown excellent results and hold great potential. Fluoride PET/CT Skull Base to Mid-Thigh Fluoride PET/CT is not routinely used in the evaluation of prostate cancer recurrence. PSMA PET/CT Skull Base To Mid-Thigh PSMA was approved by FDA in December 2020 for patients with suspected prostate cancer metastasis who are potentially curable with previous surgery or RT in the University of California, Los Angeles, and the University of California, San Francisco [82]. In a study with 50 patients with BCR after RT who underwent PSMA PET/CT and salvage prostatectomy, the sensitivity and positive predictive value of PSMA PET/CT were both 100%. A separate analysis per lymph node revealed a sensitivity, specificity, positive predictive value, and negative predictive value as 34.78%, 100%, 100%, and 97.52%, respectively [129]. Radiography Skeletal Survey Radiographic survey is not routinely used in the evaluation of prostate cancer recurrence.
Post Treatment Follow up of Prostate Cancer. Choline PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/MRI for follow-up of a patient with a clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for follow-up of a patient with a clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments. PET Using Other Agents: There are many additional prostate-specific tracers that are not FDA approved, including 11C-acetate [70,71], 18F-choline [72-74], Bombesin, 18F-fluorodihydrotestosterone [78] that are in various stages of investigation and have been reported to detect local and metastatic recurrent disease in patients with biochemical failure after local treatment. These agents remain investigational, but some have shown excellent results and hold great potential. Fluoride PET/CT Skull Base to Mid-Thigh Fluoride PET/CT is not routinely used in the evaluation of prostate cancer recurrence. PSMA PET/CT Skull Base To Mid-Thigh PSMA was approved by FDA in December 2020 for patients with suspected prostate cancer metastasis who are potentially curable with previous surgery or RT in the University of California, Los Angeles, and the University of California, San Francisco [82]. In a study with 50 patients with BCR after RT who underwent PSMA PET/CT and salvage prostatectomy, the sensitivity and positive predictive value of PSMA PET/CT were both 100%. A separate analysis per lymph node revealed a sensitivity, specificity, positive predictive value, and negative predictive value as 34.78%, 100%, 100%, and 97.52%, respectively [129]. Radiography Skeletal Survey Radiographic survey is not routinely used in the evaluation of prostate cancer recurrence.